Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Biogen Ma Inc patents (2018 archive)


Recent patent applications related to Biogen Ma Inc. Biogen Ma Inc is listed as an Agent/Assignee. Note: Biogen Ma Inc may have other listings under different names/spellings. We're not affiliated with Biogen Ma Inc, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "B" | Biogen Ma Inc-related inventors


Neuroprotection in demyelinating diseases

Methods of treating neurological disorders characterized by extensive demyelination and/or axonal loss are provided. Examples of such disorders include secondary progressive multiple sclerosis and devic's disease. ... Biogen Ma Inc

Molecular signatures for use in diagnosis and response to treatment analysis of autoimmune diseases

The present invention relates to molecular signatures that can be used to identify patients diagnosed with an autoimmune disease, in particular with systemic lupus erythematosus for treatment with a cd40 or cd40l antagonist such as anti-cd40 antibody, anti-cd40l antibody or a binding fragment thereof. The signatures can also be used to monitor target engagement and response to treatment.. ... Biogen Ma Inc

Anti-cd40 antibody formulations

Provided herein, in some aspects, are low viscosity, low aggregation propensity, high anti-cd40 antibody concentration formulations.. . ... Biogen Ma Inc

Pharmaceutical compositions containing dimethyl fumarate

Provided herein are compositions containing compounds, or pharmaceutically acceptable salts, that metabolize to monomethyl fumarate with certain pharmacokinetic parameters and methods for treating, prophylaxis, or amelioration of neurodegenerative diseases including multiple sclerosis using such compositions in a subject, wherein if the compositions contain dimethyl fumarate, the total amount of dimethyl fumarate in the compositions ranges from about 43% w/w to about 95% w/w.. . ... Biogen Ma Inc

Nrf2 screening assays and related methods and compositions

Provided are certain methods of screening, identifying, and evaluating neuroprotective compounds useful for treatment of neurological diseases, such as, e.g., multiple sclerosis (ms). The compounds described upregulate the cellular cytoprotective pathway regulated by nrf2. ... Biogen Ma Inc

Methods of preventing and removing trisulfide bonds

The present invention pertains to methods of preventing and eliminating trisulfide bonds in proteins such as antibodies. In one embodiment, trisulfide bonds in proteins are converted to disulfide bonds as part of chromatographic purification procedures. ... Biogen Ma Inc

Anti-vla-4 antibodies

This invention relates to alpha-4 binding antibodies, and fragments thereof.. . ... Biogen Ma Inc

Immunoglobulin formulation and method of preparation thereof

A stable aqueous pharmaceutical formulation comprising a therapeutically effective amount of an antibody, polysorbate 80, a buffer which inhibits polysorbate oxidation is described along with methods of making the preparation. Also described are formulations with high antibody concentrations which maintain fixed volumes and which may be used on patients of variable weight.. ... Biogen Ma Inc

Pharmaceutical compositions containing dimethyl fumarate

Provided herein are compositions containing compounds, or pharmaceutically acceptable salts, that metabolize to monomethyl fumarate with certain pharmacokinetic parameters and methods for treating, prophylaxis, or amelioration of neurodegenerative diseases including multiple sclerosis using such compositions in a subject, wherein if the compositions contain dimethyl fumarate, the total amount of dimethyl fumarate in the compositions ranges from about 43% w/w to about 95% w/w.. . ... Biogen Ma Inc

Adipate forms and compositions of biaryl inhibitors of bruton's tyrosine kinase

The present invention provides compounds and compositions thereof which are useful as inhibitors of bruton's tyrosine kinase and which exhibit desirable characteristics for the same.. . ... Biogen Ma Inc

Assays for evaluating cell culture reagents

Some aspects of the present disclosure provide methods, compositions and kits for identifying one or more reagents, such as a culture medium, that are effective for recombinant protein production.. . ... Biogen Ma Inc

Manganese supplementation for control of glycosylation in mammalian cell culture process

The present invention pertains to a cell culture medium comprising manganese as a media supplement, which was shown to control recombinant protein glycosylation and methods of using thereof. The present invention further pertains to a method of controlling or manipulating glycosylation of a recombinant protein of interest in a large scale cell culture.. ... Biogen Ma Inc

Pharmaceutical bead formulations comprising dimethyl fumarate

The present invention provides novel pharmaceutical compositions of dimethyl fumarate. The pharmaceutical compositions of the present invention are in the form of a bead and comprise (i) an inert core; (ii) a first layer surrounding the inert core, wherein the first layer comprises dimethyl fumarate; and (iii) an enteric coating surrounding the first layer. ... Biogen Ma Inc

Lingo-1 antagonists and uses for treatment of demyelinating disorders

Methods, compositions and kits comprising an anti-lingo antibody molecule are described herein useful for detecting and/or treating a cns demyelinating disease.. . ... Biogen Ma Inc

05/24/18 / #20180143204

Anti-vla-4 related assays

Methods and apparatus for assaying the level of analytes in a sample, related to vla-4, are disclosed. A method of decreasing the level of an anti-integrin antibody in a subject is described including a) contacting a biological sample from a subject with a detectable capture agent associated with a substrate, wherein the capture agent can bind an anti-integrin antibody in the sample; b) detecting binding of the capture agent with the level of the anti-integrin antibody; and c) treating the subject with plasma exchange until the level of the anti-integrin antibody in the sample reaches a predetermined level.. ... Biogen Ma Inc

05/17/18 / #20180133233

Bicyclic aryl sphingosine 1-phosphate analogs

Compounds that have agonist activity at one or more of the s1p receptors are provided. The compounds are sphin-gosine analogs that, after phosphorylation, can behave as agonists at s1p receptors.. ... Biogen Ma Inc

05/10/18 / #20180127507

Methods of treating progressive forms of multiple sclerosis

The present disclosure relates to methods of treating individuals suffering from progressive forms of multiple sclerosis.. . ... Biogen Ma Inc

04/05/18 / #20180093973

Biaryl inhibitors of bruton's tyrosine kinase

The present invention provides compounds and compositions thereof which are useful as inhibitors of bruton's tyrosine kinase and which exhibit desirable characteristics for the same.. . ... Biogen Ma Inc

03/29/18 / #20180088127

Methods and products for evaluating an immune response to a therapeutic protein

The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. Aspects of the invention relate to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of a vla4 binding antibody (e.g., natalizumab).. ... Biogen Ma Inc

03/22/18 / #20180079796

Anti-tnf-alpha polypeptide composition and use thereof

The invention provides a composition comprising an anti-tumor necrosis factor (tnf)-alpha polypeptide, wherein the composition produces a reduced level of immunogenicity when administered to a subject, as well as a treatment method involving the administration of the composition.. . ... Biogen Ma Inc

03/08/18 / #20180065974

Bruton's tyrosine kinase inhibitors

The present invention provides compounds useful as inhibitors of btk, compositions thereof, and methods of using the same.. . ... Biogen Ma Inc

03/08/18 / #20180064386

Methods for evaluating patients

Methods for evaluating subjects having conditions associated with loss of muscle function (e.g., a motor neuron disease, a neuromuscular disease, or a myopathy) by measuring muscle function (e.g., muscle strength) are disclosed.. . ... Biogen Ma Inc

02/08/18 / #20180037939

Methods and compositions for detecting therapeutic nucleic acids

The present disclosure relates, in some aspects, to the field of nucleic acid detection. Disclosed herein are methods and compositions for detecting nucleic acids using synthetic single-stranded ribonucleic acids (rnas). ... Biogen Ma Inc

02/01/18 / #20180028511

S1p modulating agents

Compounds of formula (i) or (ii) can modulate the activity of s1p receptors.. . ... Biogen Ma Inc

01/11/18 / #20180012354

Methods for improved measurements of brain volume and changes in brain volume

. . Methods of the disclosure may include obtaining a first set of medical images at a first time point and a second set of medical images at a second time point, each set including at least two medical images. First and second algorithms may be used to calculate, respectively, first and third brain volume (bv) values at the first time point based on two or more images from the first set of medical images and second and fourth bv values at the second time point based on two or more images from the second set of medical images. ... Biogen Ma Inc

01/04/18 / #20180002356

Heterobicyclic sphingosine 1-phosphate analogs

Compounds that have agonist activity at one or more of the s1p receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at s1p receptors.. ... Biogen Ma Inc

01/04/18 / #20180000770

Methods of treating multiple sclerosis

Provided herein are methods of treating multiple sclerosis with a fumarate, wherein the fumarate is a dialkyl fumarate, a monoalkyl fumarate, a combination of a dialkyl fumarate and a monoalkyl fumarate, a prodrug of monoalkyl fumarate, a deuterated form of any of the foregoing, or a pharmaceutically acceptable salt, clathrate, solvate, tautomer, or stereoisomer of any of the foregoing, or a combination of any of the foregoing. The methods provided herein improve the safety of treatment by informing and monitoring patients undergoing treatment regarding progressive multifocal leukoencephalopathy, and/or by monitoring lymphocyte count.. ... Biogen Ma Inc








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Biogen Ma Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Biogen Ma Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###